CSF2 and COVID-19: Based on the hypothesis of lost GM-CSF-mediated differentiation of homeostatic AlvMφ, inhalation of recombinant human GM-CSF has been shown to boost antiviral immune responses without systemic adverse effects in hypoxic COVID-19 patients [208].